Abstract:Amin E Nawar Ophthalmology Department, Faculty of Medicine, Tanta University, Tanta, Egypt Correspondence: Amin E Nawar, Ophthalmology Department, Faculty of Medicine, Tanta University, Tanta, 31516, Egypt, Tel +20 1140095692, Email Purpose: The present study evaluated the efficacy of combined suprachoroidal injection of triamcinolone acetonide (TA) using a modified microneedle with intravitreal injection of ranibizumab in branch retinal vein occlusion (BRVO) patients. Patients and methods: This is a prospective randomised interventional study that was conducted on 60 eyes of 60 patients with non ischemic BRVO. Patients were divided in two groups, group (1) 30 patients who received intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab, group (2) included 30 patients who received baseline combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL), both groups received monthly injection of ranibizumab on pro-re-nata (PRN) regimen for 1 year duration of the study. Results: Group 2 received less number of injections (2.47 ± 1.2) as compared to group 1 (4.4 ± 1.5). Both groups achieved significant reduction of central macular thickness (CMT) after 12 months of injection with p value < 0.001. Both groups showed significant improvement of best corrected visual acuity (BCVA) after 12 months with p value < 0.001. Group 2 showed more significant improvement of BCVA after 6 and 12 months. The baseline CMT and the number of injections were the main predictors of the final BCVA in group 1, while the baseline BCVA was the only predictor of final BCVA in group 2. Conclusion: Combined suprachoroidal injection of TA using this modified microneedle with intravitreal injection of ranibizumab resulted in more significant improvement of BCVA and reduction of CMT compared with ranibizumab monotherapy with no reported ocular or systemic side effects. The study was prospectively registered with clinical trial.gov ID (NCT04690608) in 27-12-2020. Keywords: branch retinal vein occlusion, suprachoroidal injection, triamcinolone acetonide Retinal vein occlusion (RVO) is the second most common retinal vascular disorder, branch retinal vein occlusion (BRVO) represents about 80% of RVO cases. 1,2 BRVO occurs on top of occlusion of a first-or second-order retinal vein at the site of arteriovenous (AV) crossing, 3,4 subsequently, macular edema (ME) and retinal non perfusion develop on top of elevated levels of vascular endothelial growth factor (VEGF). 5 Retinal non perfusion results in vitreous hemorrhage if affecting the retinal periphery 6,7 or severe visual deterioration if the macula was affected. 8 Nowadays, multiple treatment modalities are present for the management of BRVO. Laser can improve retinal oxygenation, decrease vascular leakage and reduce macular edema. 9 In addition, anti-VEGF agents like ranibizumab (Lucentis ® , Novartis, Basel, Switzerland) can inhibit angiogenesis and reduce leakage and macular edema, but the main drawback of these agents that they require multiple injections to maintain a stable effect. 10 Triamcinolone Acetonide (TA) is a synthetic corticosteroid that can be used for management of various intra-ocular inflammatory disorders in the last years, 11 it can improve visual acuity and decrease macular edema. 12 Nowadays, steroid implants are available like Ozurdex ® and Iluvein ® . Ozurdex ® (Allergan, Inc., Irvine, USA) is a dexamethasone implant that can slowly release steroids into the vitreous cavity for 6 months duration, it has less complication rate if compared to intravitreal Triamcinolone Acetonide (IVTA) but still can result in elevation of the intraocular pressure (IOP) and acceleration of cataract progression. 13 This raised the need to search for other routes of TA delivery to the eye instead of intravitreal route to minimize side effects of TA. The suprachoroidal space is a novel route for TA delivery to the posterior segment of the eye, in a study done on rabbits, TA achieved higher concentration in the posterior segment after suprachoroidal injection than intravitreal route with less concentration in the anterior segment and the lens, hence, suprachoroidal route results in less complication rate. 14 Multiple recent studies proved the efficacy of suprachoroidal injection of TA in cases of uveitis and RVO with longer duration of action and fewer side effects. 15–17 The present study was designed to evaluate the use of a modified inexpensive microneedle for suprachoroidal injection of TA combined with intravitreal injection of ranibizumab in cases of BRVO. A prospectiv -Abstract Truncated-

Early adoption of triamcinolone acetonide suprachoroidal injection for uveitic macular edema: a physician survey

Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis

What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023

Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis

Refractory post-surgical cystoid macular edema managed following suprachoroidal microcatheterization and delivery of triamcinolone

Suprachoroidal Space Injection Technique: Expert Panel Guidance

Choroidal Changes After Suprachoroidal Injection of Triamcinolone Acetonide in Eyes With Macular Edema Secondary to Retinal Vein Occlusion

Safety and Efficacy of Suprachorodial Injection of Triamcinolone Acetonide: Review of a Novel Treatment

Incidence of Steroid-Related Ocular Hypertension and Cataract Formation After Subtenon Triamcinolone in Non-Uveitic Pediatric Patients

Safety and Tolerability of Suprachoroidal Axitinib Injectable Suspension, for Neovascular Age-related Macular Degeneration; Phase I/IIa Open-Label, Dose-Escalation Trial

Resolution of Postoperative Cystoid Macular Edema with a Suprachoroidal Triamcinolone Acetonide Injectable Suspension

Modified inexpensive needle for suprachoroidal triamcinolone acetonide injections in pseudophakic cystoid macular edema

The Efficacy and Safety of Adalimumab in Treating Pediatric Noninfectious Chronic Anterior Uveitis With Peripheral Retinal Vascular Leakage: A Pilot Study

Managing solar retinopathy with suprachoroidal triamcinolone acetonide injection in a young girl: a case report

Clinical Observation of Intravitreal Injection of Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion

Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients

Delivery of steroids into the eye for the treatment of macular edema

Common Practice Patterns in the Diagnosis and Management of Acute Retinal Necrosis: A Survey Study of Uveitis Specialists

Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center

Posterior sub-tenon injection of triamcinolone in non-resolving vitreoretinitis - A case report

Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents